C hemokines play a pivotal role in orchestrating the targeted movement of immune cells to sites of inflammation. more than 40 chemokines and approximately 20 chemokine receptors have been described. 1 the chemokines are generally categorized according to a conserved cysteine motif into the c, cc, cXc, and cX3c classes. monocyte chemoattractant protein 1 (mcp-1) is a cc-type chemokine, known to direct monocytic infiltration in the context of several inflammatory diseases via binding to ccr2, the only known mcp-1 receptor. in humans, ccr2 exists in two c-terminal splice variants, ccr2a and ccr2B. Based on the differences in their c-terminal cytoplasmic domains, ccr2B, the predominant splice variant in human monocytes, is mostly expressed at the cell surface, whereas a large fraction of ccr2a is retained intracellularly. 2 like other chemokine receptors, ccr2 belongs to the superfamily of 7-transmembrane helical g-protein-coupled receptors (gpcrs). this protein family encompasses the most frequently addressed drug targets pursued by the pharmaceutical industry. however, there are distinct challenges associated with gpcrs as drug targets (e.g., those based on the ligand-modulated conformational diversity and functionality of these transmembrane receptors). in particular, the observation of ligand-induced selective signaling, 3, 4 also referred to as ligand-biased signaling, has demonstrated the need for a broad experimental profiling of gpcr drug candidates with respect to various downstream signaling pathways. an excellent example of successfully employing such an experimental matrix to gpcr-directed drug discovery was provided by richman and colleagues. 5 in their work, they identified agonists of gpr109a capable of selectively eliciting the desired antilipolytic effects while avoiding the induction of the skin flush response, an unfavorable, quite common side effect caused by unbiased gpr109a activation. interestingly, those antilipolytic gpr109a agonists that did not produce flushing also failed to induce gpr109a internalization and erk1/2 phosphorylation. similarly, in the case of ccr2, divergent apparent potencies have previously been observed for two reference ccr2 antagonists with respect to inhibition of mcp-1 binding, gtpγs binding, increase of cytosolic ca 2+ , erk phosphorylation, and chemotaxis. 6 in recent years, high-throughput fluorescence microscopic imaging in combination with automated image analysis, also referred to as high-content analysis (hca), 7 was introduced into pharmaceutical drug discovery programs. in hca assays, the biomolecules of interest are labeled with various fluorophores that can be monitored in parallel at different wavelengths. image analysis software quantifies the redistribution of the fluorophore-labeled biomolecules as a consequence of a pharmacological effect. the hca format has been applied to analyze gpcr internalization and signaling many times. [8] [9] [10] [11] [12] in this work, we used primary human monocytes to establish an mcp-1 internalization assay. the mcp-1-induced internalization of ccr2 has previously been shown to be β-arrestin dependent. 13 β-arrestins are cytoplasmic proteins that are recruited to the plasma membrane by gpcr kinase (grk)phosphorylated gpcrs. 14 apart from their indirect influence on g-protein signaling by the physical interference with the gpcr-g-protein-coupling, β-arrestins have been found to directly mediate many g-protein-independent gpcr functions, including those of chemokine receptors. [15] [16] [17] our incentive to establish an hca internalization assay for the identification and characterization of ccr2 antagonists was twofold. First, a previous observation-that a ccr2 fusokine antagonist specifically interfering with the recruitment of β-arrestin 2 to the membrane proved to be a potent inhibitor of inflammation 18prompted us to include ccr2 internalization in the assay readout. second, we wished to discriminate, at the single cell level, between ligand binding at the cell surface and internalization of the liganded receptor to allow detection of compounds interfering with receptor internalization by interacting with an allosteric site. the latter is difficult to accomplish with already existing assay formats, such as those based on fluorescence-activated cell sorting (Facs). 19 the use of primary human monocytes expressing the human ccr2 isoforms at physiologic densities in contrast to nonphysiological recombinant mammalian cell hosts overexpressing single ccr2 variants 6 should further increase the pharmacotherapeutic predictivity of the internalization assay regimen described here.
MAterIALS And MetHodS

Materials
Ficoll-paque plUs (cat. 17144002) was from ge healthcare Bio-sciences (little chalfont, Uk). the monocyte isolation kit ii (cat. 130091153) and macs separation ls columns (cat. 130042401) were purchased from miltenyi Biotec (auburn, ca). Dulbecco's phosphate-buffered saline (pBs) without ca 2+ and mg 2+ (1xD-pBs; cat. h15-002) was from paa laboratories (pasching, austria). eDta (versen) 1% (w/v) in pBs without ca 2+ For the chemotaxis assay, the chemotx Disposable chemotaxis system (5-µm pore size; cat. 116-5) from neuro probe (gaithersburg, mD) and the optiplate-96 (cat. 6005290) from perkinelmer life and analytical sciences in combination with the celltiter-glo luminescent cell viability assay (cat. g7571) from promega (madison, Wi) were used. For the 125 i-hmcp-1 hccr2 spa binding assay, the polyvinyltoluene wheat germ agglutinin scintillation beads (pvt-Wga beads; cat. rpnQ0001) were from ge healthcare. a human acute monocytic leukemia cell line (thp-1 cells, DsmZ no. acc 16) was obtained from DsmZ gmbh (Braunschweig, germany). the thp-1 cells were cultured with rpmi 1640 medium with glutamaX and 25 mm hepes (cat. 72400-021) supplemented with 1% (v/v) nonessential amino acids (neaa; cat. 11140-035) and 10% (v/v) fetal calf serum (Fcs; cat. 10500-064) from invitrogen.
all other materials were of the highest grade commercially available.
Methods
Semi-automated hMCP-1_AF647 internalization assay on primary human monocytes. peripheral blood mononuclear cells (pBmcs) were isolated from human buffy coat preparations obtained from the german red cross Blood Bank in Ulm (germany) by density gradient centrifugation using Ficoll-paque plUs. Untouched monocytes were prepared by depletion of nonmonocytes (negative selection) using the monocyte isolation kit ii from miltenyi Biotec according to the manufacturer's protocol. the purity of the isolated monocytes was assessed by hemacolor staining of a cytospin preparation. the freshly isolated monocytes were plated onto type i collagen-coated BD 384-well assay plates (aps) using an eight-channel pipette with a cell density of 25 000 cells/well in 30 µl assay buffer (1× hBss, 10 mm hepes, 0.0375% [w/v] sodium bicarbonate, and 0.1% [w/v] Bsa). the lid-covered aps were then incubated for 60 min at 37 °c under 5% (v/v) co 2 . compound source plates (csps) were prepared by making a 3.16-fold serial dilution of the test compounds in 100% Dmso. next, the compounds of the csps were diluted 1:200 in compound buffer (1× hBss, 10 mm hepes, 0.0375% [w/v] sodium bicarbonate) into a compound buffer dilution plate (cBDp) using the cyBi-Well 384 simultaneous pipettor (cyBio ag, Jena, germany). then, 10 µl/well of the diluted test compounds was transferred from the cBDp to the ap, again using the cyBi-Well 384 simultaneous pipettor. the ap was incubated for 30 min at room temperature (rt). then, 10 µl/well of hmcp-1_aF647 in assay buffer was added, adjusting the concentration of hmcp-1_aF 647 to 10 nm, the approximate ec 80 value of this and the hca and whole-blood assays, as measured in this case by titrating hmcp-1_aF647 to the supernatant of vehicle-pretreated primary monocytes.
this was followed by an incubation at 37 °c under 5% (v/v) co 2 for the indicated time periods or for 45 min in the final protocol. Wells containing a final concentration of 10 nm of hmcp-1_aF647 and 0.1% (v/v) Dmso served as positive controls ("high"), and wells supplemented with 1 µm reference antagonist Bms ccr2 22 and treated with 10 nm agonist served as negative controls ("low").
cells were fixed at rt with 4% (v/v) formaldehyde in pBs, and nuclei were stained using 1 µm hoechst 33342, followed by storage of the cells at 4 °c. imaging with the in cell analyzer 3000 was performed using the 364-nm laser for fluorescence excitation of the hoechst 33342 dye and the 647-nm laser for the aF647/hmcp-1 signal.
Image analysis. For the hmcp-1_aF647 internalization assay based on fluorometric imaging by the in cell analyzer 3000, images were analyzed using the granularity algorithm (grn2) contained in the in cell analyzer 3000 analysis package. Briefly, the grn2 algorithm identifies the nuclei as pixel accumulations above a specified intensity threshold in the blue (nuclear) channel image. in a specified dilated "cytoplasmic" mask region around these nuclei, grains of a predefined size and intensity corresponding to the internalized agonist were identified. the Fgrains value was calculated as described previously. 6 IC 50 determination and statistical data analysis. Using the graphpad prism software version 4.03 (graphpad software, la Jolla, ca) or a proprietary high-throughput screening (hts) application, dose-response curves were fitted to the following equation:
where x is the concentration of the test compound, mean high is the mean of the "high" values (control values obtained by treatment with agonist in the presence of vehicle), mean low is the respective number for the "low" values (control values obtained by treatment with agonist in the presence of reference antagonist), and Hill is the hill coefficient. Z′ values and signal-to-noise (s/n) ratios were calculated as described previously. 6 MCP-1-induced increase in cytosolic Ca 2+ in primary human monocytes. primary human monocytes were isolated from buffy coat preparations of healthy donors as described above. after loading the monocytes with the calcium indicator Fluo-4 am, the change in cytosolic ca 2+ concentration was measured with the Flipr tetra at an excitation wavelength of 470 to 490 nm and an emission wavelength of 515 to 575 nm. the first 2 s of the fluorescence measurements were used to detect the baseline. the pipetting system applied the test compound at different concentrations for an incubation time of 180 s. then, the cells were treated with mcp-1 at 10 nm. (When measuring the increase of cytosolic ca 2+ , the measured ec 80 value for mcp-1 was 8 nm; for simplicity and to enhance congruence between this and the hca and whole-blood assay, 10 nm agonist was chosen, the concentration determined as the ec 80 value for the latter two formats by inhibition of fluorophore-labeled mcp-1 binding.) For quantification of the apparent inhibitory potencies of test compounds, the signal intensity was integrated for 83 s after mcp-1 addition.
Chemotaxis of THP-1 cells. chemotaxis was assayed by suspending thp-1 cells at a concentration of 7 × 10 6 cells/ml in assay medium (hybridomed DiF1000 containing 5% [w/v] hsa in pBs with ca 2+ and mg 2+ ) and treating the cells with test compounds at the indicated concentrations for 30 min at 37 °c under 5% (v/v) co 2 . the lower compartment of the chemotx plate was filled with assay medium containing the ec 80 of hmcp-1 with regard to chemotaxis (800 pm). then, 500 000 of the compound-treated cells were placed on the top of the polycarbonate filter, and the whole chemotx plate was incubated for 3 h at 37 °c under 5% (v/v) co 2 . test compound-mediated antagonism of chemotaxis was measured by determining the cell number of a 100-µl aliquot of the cell suspension from the lower well by using the celltiter-glo luminescent viability assay.
Binding of hMCP-1_AF647 to CCR2 in human whole blood. From healthy donors, 84 µl of human whole blood was anticoagulated with 16 µl of acD buffer (75 mm sodium citrate, 38 mm citric acid, 120 mm glucose, ph 6.5). then, 1 µl with different concentrations of test compounds was added, and the mixture was incubated for 15 min at 37 °c under 5% (v/v) co 2 . next, 99 µl of working solution with hmcp-1_aF647 (final concentration 10 nm; i.e., the approximate ec 80 concentration, determined by titration as described above for the hca internalization assay) and a pe-labeled antihuman cD14 antibody (final dilution 1:360) were added to the sample, followed by incubation of the mixture for 60 min at 37 °c under 5% (v/v) co 2 . the sample was centrifuged (1200 rpm, 5 min, 4 °c), and the red blood cells were lysed by addition of 1200 µl lysing solution (155 mm nh 4 cl, 10 mm khco 3 , 0.1 mm eDta), followed by incubation of the mixture for 30 min on ice. after two washing steps with hBss (without ca 2+ and mg 2+ , supplemented with 20 mm hepes, 0.2% [w/v] Bsa, ph 7.4), the remaining cells were fixed by resuspension in BD cellFiX solution (1:10 in pBs). the fluorescence of the cells was measured with the BD lsrii flow cytometer using excitation wavelengths of 633 nm and 488 nm. cells positive for pe-labeled cD14 were gated, and hmcp1_aF647-positive cells within this population were counted and analyzed using BD Facs Diva software.
Binding of radiolabeled hMCP-1 to THP-1 cell membranes (scintillation proximity assay [SPA]
). a crude membrane preparation of thp-1 membranes containing ccr2 was adjusted with assay buffer (25 mm hepes/naoh, ph 7.2; 5 mm mgcl 2 ; 0.5 mm cacl 2 ; and 0.2% [w/v] Bsa) to a concentration of 5 µg protein/µl. pvt-Wga-spa beads were diluted to a concentration of 8 mg beads/ml with assay buffer. For preparation of the membrane bead suspension, membranes and beads were incubated at a ratio of 1:2 (v:v) for 30 min at rt under end-over-end rotation. test compounds were dissolved in 100% Dmso to a concentration of 10 mm and were further diluted with 100% Dmso to 1 mm. all additional compound dilutions were done with assay buffer, diluting Dmso to a final concentration of 1% (v/v). compounds and membrane bead suspension were incubated with 100 pm 125 i-hmcp-1 (<25 000 cpm/10 µl), where approximately 80% of the receptors should be saturated in the absence of an antagonist. Bound radioactivity was determined by a beta-counter after 6 h. Determination of the affinity of test compounds was calculated by curve fitting of experimental data using graphpad prism software version 4.03, employing the cheng-prusoff correction 20 to derive an apparent dissociation equilibrium constant k i .
reSuLtS
hMCP-1 binding and CCR2 internalization in primary human monocytes
in this work, we established an hca assay format to determine the antagonistic properties of test compounds at ccr2 of human primary monocytes. to study ccr2-ligand-mediated effects on the cellular localization of ccr2 by confocal fluorescence microscopy, monocytes freshly isolated from peripheral blood of healthy human donors were seeded onto type i collagencoated 384-well plates. For the evaluation of the assay format, the high-affinity ccr2 chemokine receptor antagonist Bms ccr2 22 21 was employed. alexa Fluor 647-conjugated hmcp-1 served to visualize hmcp-1 binding to ccr2 and subsequent receptor ligand cointernalization. figure 1 shows that the fluorescently labeled receptor agonist hmcp1_aF647 was found both at the plasma membrane and in large intracellular perinuclear aggregates ( fig. 1a , shown in red). treatment with an excess of unlabeled hmcp-1 resulted in a strong decrease of the red signal as a consequence of the displacement of the labeled by the unlabeled chemokine ( fig. 1b) , thus confirming the binding specificity of the labeled species. figure 1c demonstrates that Bms ccr2 22 prevents both the binding and the internalization of fluorescently labeled hmcp1_ aF647 (red channel). in the following experiments, the internalization of hmcp1_aF647 by human primary monocytes was employed to establish an hca assay for the characterization of ccr2 antagonists.
Establishment of an HCA assay using primary human monocytes
hmcp-1_aF647 internalization by primary human monocytes was monitored using the in cell analyzer 3000 for automated fluorescence microscopic imaging and the image analysis software raven (ge healthcare Bio-sciences, little chalfont, Uk) for the quantification of ccr2 antagonistic effects. the hca assay was established by seeding primary human monocytes onto type i collagen-coated 384-well microtiter plates (mtp). compounds to be tested were incubated with the cells in the mtp prior to the addition of hmcp-1_ aF647 to improve the probability of detecting ccr2 antagonists with slower on-rates. figure 2 illustrates the principle of the image analysis. Briefly, the grn2 algorithm detected the nuclei of the monocytes as pixel accumulations above a specified intensity threshold in the blue channel image (nuclear masks in fig. 2b,e ). in rectangular search regions of a prespecified extension around these nuclei (larger rectangles in fig. 2c,f) , pixel accumulations of a predefined size and fluorescence intensity were identified in the red channel image (small squares in fig. 2c,f) . the fluorescence intensity across the latter red channel pixel accumulations was integrated and normalized across the cell number of the whole image in the Fgrains value. this value corresponds to the average amount of internalized hmcp-1_aF647 for the cell population observed in one image. to determine the specific requirement of collagen coating of the mtps, cells were allowed to adhere to type i collagen-coated or tc-treated polystyrene surfaces ("uncoated") and analyzed for internalization of hmcp-1 in the absence ("high") or presence of 300 nm Bms ccr2 22 ("low") ( fig. 3) . interestingly, monocytes seeded onto the type i collagen-coated plastic surface exhibited a 2.4 times higher degree of mcp-1 internalization in comparison to the cells adhered to tc-treated polystyrene. consequently, the type i collagen-coated mtps were used as assay plates throughout this work.
to define the optimal conditions with regard to assay quality statistics, a time course experiment for fluorophore-labeled hmcp-1 internalization between 2 and 120 min was performed (table 1). image analysis using the grn2 granularity analysis algorithm was based on approximately 64 000 cells per time point collected across eight mtp wells. the microscopic images revealed an approximately linear increase of internalized hmcp-1 over the first 45 min, rendering this time span optimal for fIG. 1. subcellular localization of ccr2 and internalization of fluorescently labeled hmcp-1 in human monocytes. human monocytes were seeded onto collagen type i-coated 384-well plates and treated either with 20 nm hmcp1_aF647 (a) or with a mixture of 20 nm hmcp-1_aF647 and 200 nm unlabeled hmcp-1 (b). to study antagonism at ccr2, the leukocytes were pretreated with 300 nm of the ccr2 antagonistic compound Bms ccr2 22 (30 min at room temperature) before incubation with 20 nm hmcp-1_aF647 for 45 min at 37 °c (c). the monocytes were fixed with formaldehyde, and nuclei were stained with hoechst 33342 dye. images were taken using the opera Qehs equipped with a 60× water immersion objective. the respective fluorophores were excited with a 405-nm laser for the hoechst 33342 dye (blue channel: nuclei) and a 635-nm laser for aF647 (red channel: hmcp-1).
fIG. 2.
Quantification of ccr2 antagonistic effects on the internalization of the fluorescently labeled agonist hmcp-1_aF647 by image analysis. human monocytes were seeded onto collagen type i-coated 384-well plates and treated with 300 nm of the ccr2 antagonist Bms ccr2 22 (a-c) or incubated with vehicle (30 min at room temperature) (d-f) before the addition of 20 nm hmcp-1_aF647 (45 min at 37 °c). imaging of the fixed cells was conducted using the in cell analyzer 3000 with the 364-nm laser for fluorescence excitation of the hoechst 33342 dye and the 647-nm laser for fluorescence excitation of aF647. the internalization of the fluorophore-labeled hmcp-1 with ccr2 upon receptor activation resulted in the formation of granules within the vehicle-treated monocytes. the granularity algorithm grn2 of the in cell analyzer 3000 software package was used to identify and quantify these granules (b, c, e, f). adapted analysis parameter settings are shown as the nuclear mask (b, e), the measurement region of the dilated nuclear mask (large white boxes; c, f), and the granule regions (small white boxes; c, f). antagonist testing. in addition, the Z′ and the s/n values increased up to the 45-min time point and remained unchanged or even declined afterwards. thus, we selected the 45-min incubation for all further experiments, providing robust assay quality statistics with a Z′ factor of 0.82 and an s/n ratio of 18:1.
next, the concentration dependence of the Bms ccr2 22-mediated effects on the hmcp-1_aF647 internalization was determined. to this end, freshly isolated monocytes were first treated with this reference inhibitor at concentrations increasing from 0 to 316 nm and then exposed to 10 nm hmcp-1_aF647. after 45 min, the leukocytes were fixed with formaldehyde, and the nuclei were stained using the hoechst 33342 dye. imaging was performed with the in cell analyzer 3000. Under these conditions, Bms ccr2 22 inhibited the internalization of hmcp1_aF647 with an ic 50 value of approximately 2 nm ( fig. 4) . this value is in good agreement with data from the literature: cherney and coworkers, 21 for example, reported ic 50 values of 5.1 nm, 18 nm, and 1 nm for Bms ccr2 22 with regard to mcp-1 binding to ccr2, mcp-1-mediated increase in cytosolic calcium, and chemotaxis, respectively.
Despite the fact that we worked with primary human monocytes isolated from different donors, the established hca assay was robust with excellent Z′ statistics and showed only little day-to-day variabilities.
Semi-automated hMCP-1_AF647 internalization assay on primary human monocytes
to adapt the hmcp-1_aF647 internalization bioassay procedure for the characterization of ccr2 antagonists to a higher throughput, we transferred the hca assay to a semi-automated format. to this end, the test compound titration in Dmso was fIG. 3. Degree of internalization of the fluorescently labeled agonist hmcp-1_aF647 into monocytes seeded onto type i collagen-coated and a tissue culture (tc)-treated polystyrene surface. isolated human monocytes adhering to type i collagen-coated or tc-treated polystyrene ("uncoated") surfaces were incubated with vehicle ("high" values) or 300 nm of the ccr2 antagonist Bms ccr2 22 ("low" values) before the addition of 10 nm hmcp-1_aF647 (45 min at 37 °c). after the fixation of the leukocytes with formaldehyde, imaging was performed by using the in cell analyzer 3000 with the 364-nm laser for fluorescence excitation of the hoechst 33342 dye and the 647-nm laser for fluorescence excitation of aF647. the accumulation of hmcp-1_aF647 in granules was quantified using the granularity algorithm grn2. to define the optimal conditions with regard to assay quality statistics, a time course experiment was performed for fluorophore-labeled hmcp-1 internalization. to this end, human monocytes seeded onto collagen type i-coated 384-well plates were treated for 30 min at room temperature with vehicle ("high" values) or 300 nm of the ccr2 antagonistic compound Bms ccr2 22 ("low" values) before incubation for the indicated time periods at 37 °c with 10 nm hmcp-1_aF647. after fixation with formaldehyde, the fluorometric imaging of mcp-1_aF647 internalization was carried out using the in cell analyzer 3000. image analysis employing the granularity algorithm grn2 was based on approximately 64 000 cells per time point collected across eight microtiter plate (mtp) wells. the respective Z′ and signal-to-noise (s/n) values were calculated as described in the materials and methods section.
fIG. 4. concentration dependency of Bms ccr2 22-mediated effects on hmcp-1_aF647 internalization in human monocytes. human monocytes were seeded onto collagen type i-coated 384-well plates and treated with Bms ccr2 22 at concentrations increasing from 0 to 316 nm (30 min at room temperature) before the addition of 10 nm hmcp-1_aF647 (45 min at 37 °c). Fixed cells were imaged using the in cell analyzer 3000, and the accumulation of hmcp-1_aF647 in granules was quantified using the granularity algorithm grn2. at 10 nm hmcp-1_aF647, Bms ccr2 22 inhibited the internalization of the fluorescently labeled ligand with an ic 50 value of 2 nm. Data points are mean ± sD for images taken from 12 microtiter plate (mtp) wells for each concentration.
carried out using the epmotion 5070 device (eppendorf ag, hamburg, germany), generating the Dmso dilution plates (DDps). in parallel to this automated titration of the test compounds in Dmso, primary monocytes were manually plated using an eight-channel pipette into aps (type i collagen-coated 384-well imaging plates from BD). the manual pipetting procedure for the primary human monocytes maintained a low dead volume for this costly cell suspension. to ensure that the monocytes would withstand the subsequent liquid handling procedures, they were allowed to establish a sufficiently stable contact with the type i collagen surface in the mtp wells by incubation for 60 min at 37 °c. During this incubation period, aliquots of test compound solution were transferred from all wells of the DDp to the corresponding cBDp, diluted in aqueous assay buffer, and transferred from the cBDp to the monocytes in the ap using the cyBi-Well 384 simultaneous pipettor as described in the methods section. the fluorophore-labeled agonist hmcp-1, as well as the formaldehyde/hoechst 33342 solution for fixation and nuclear staining, was added employing a multidrop 384 dispenser, and the aps were imaged using the in cell analyzer 3000. the semi-automated assay protocol significantly increased the throughput for test compound titration and dilution into the cellular supernatant. the isolation of the monocytes from human peripheral blood buffy coats is a relatively time-consuming and complex technique with a processing time of approximately 3 h to prepare about 35 × 10 6 monocytes. in parallel to this manual procedure, both the DDps and the cBDps can be prepared in the automated way described above. after transfer of the prediluted test compounds from the cBDp to the monocytes, the residual liquid handling steps and incubation times require another 3.5 h until imaging can be initiated.
Comparison of the apparent inhibitory potencies of CCR2 antagonists between the HCA and non-HCA formats
ic 50 values of chemically related and unrelated ccr2 antagonistic test compounds were determined with the novel hmcp-1_aF 647 internalization assay and compared to the ic 50 values estimated using four other non-hca formats. For the non-hca testing, we performed a radioligand binding assay in the spa format with membranes from thp-1 cells, determination of cytosolic ca 2+ in human monocytes (ca 2+ ), a chemotaxis (ctX) assay with thp-1 cells, and hmcp-1_aF647 binding in a human whole-blood assay (WBa), as described in the materials and methods section. all assay formats, including the hca assay, were performed at the respective ec 80 of hmcp-1. figure 5 shows the linear regression plots of the ic 50 values achieved by hca versus the apparent k i values from the spa experiments ( fig. 5a) , the ic 50 values from the ca 2+ determinations (fig. 5b) , the ic 50 values from the ctX assays ( fig. 5c) , and the ic 50 values from the WBa experiments ( fig. 5d). fig. 5e shows a plot of all five p(ic 50 /k i ) parameters for each of the 24 compounds in a single graphical summary, to display the results obtained by the five methods in absolute values. the value obtained for R 2 was maximal (0.59) for hca versus WBa (fig. 5d) , followed by hca versus spa ( fig. 5a ; 0.58), hca versus ctX ( fig. 5c; 0.54) , and hca versus ca 2+ ( fig. 5b; 0.32). overall, figure 5a-d shows that there is a good correlation between hca and the other methods for some of the tested ccr2 antagonists, whereas some compounds differ markedly in their potencies with respect to the different assay readouts.
to analyze the basis for the latter deviations from the linear regression paradigm, we investigated the assay response profiles of the individual compounds in relation to their chemical properties. to define assay response profiles, the compounds and assay combinations were hierarchically clustered, using Ward's method as described in more detail in the supplementary materials. With respect to the chemical similarity, compounds with a tanimoto similarity of more than 80% were assigned to one chemotype, yielding five chemotypes (a-e) with 4, 3, 13, 2, and 2 compounds, respectively, as described in the supplementary materials.
an interesting result of this analysis is provided by compounds 10 through 22, which stand out by relatively low potencies in the ctX assay compared with the spa format, as well as to a lesser extent compared with the hca and the ca 2+ method ( fig. 5e ). eleven of these 13 compounds belong to a single chemotype c, and only 2 compounds of chemotype c do not show this particular assay response profile. thus, some substructure feature(s) of chemotype c may be associated with a negative influence on the compounds' ability to interfere with mcp-1-stimulated chemotaxis. on the contrary, all four compounds of chemotype a displayed a narrow range of ic 50 /k i values in the five assay formats and the corresponding cellular functions tested.
the other three chemotypes-b, d, and e-are underrepresented in the compound set tested. hence, the current data set does not yet allow us to associate their chemotypes with specific response profiles. however, the matrix of chemotypes versus biological profiles will be complemented with more ccr2 antagonists in the future. on the basis of such an enlarged chemobiological matrix, the signal-biased structure-activity relationships of ccr2 antagonists can be further clarified in this particular instance and the modus operandi outlined here applied to many other families of gpcr antagonists. dIScuSSIon monocyte chemoattractant protein-1 (mcp-1/ccl2) is one of the most extensively studied members of the chemokine family. Because of its importance in monocyte and macrophage (patho) physiology, the potential clinical use of ccr2 antagonists is fIG. 5. correlation between ic 50 values for ccr2 antagonistic compounds determined with the novel high-content analysis (hca) assay format and other assay formats. Different sets of chemically related and unrelated compounds were compared for their apparent antagonistic potencies determined by hmcp-1_aF647 internalization into human monocytes (hca; ic 50 ) versus (a) radioligand binding to membranes from thp-1 cells (scintillation proximity assay [spa]; k i ), (b) changes in the concentration of cytosolic ca 2+ in human monocytes (ca 2+ ; ic 50 ), (c) chemotaxis of thp-1 cells (ctX; ic 50 ), or (d) hmcp1-aF647 binding to leukocytes contained in human whole blood assay (WBa; ic 50 ). the different assays were performed at the respective ec 80 values for labeled or unlabeled hmcp-1. R-squared (R 2 ) values were calculated using graphpad prism software version 4.03. (e) absolute p(k i /ic 50 ) values of all 24 compounds in all five assay formats. the data shown in a to d were replotted to allow for a direct comparison of the various parameters with respect to individual compounds (left panel) and to visualize the ratio between the highest and the lowest potencies (right panel). multifaceted, ranging from inflammation and pain to cardiovascular and metabolic diseases. one of the barriers to clinical development of chemokine antagonists is the species specificity of some chemokines and their receptors, for example, with regard to number and expression pattern as well as pharmacological properties of specific isoforms, leading to a limited predictivity of many common preclinical animal models. 22 however, a broad range of disease-relevant human biology can already be integrated in the early drug discovery process by the use of primary human cell-based assay systems, thus improving the decision making in pharmaceutical research.
in this work, we have established a semi-automated hca assay format enabling the determination of ccr2 antagonistic properties of test compounds on human primary monocytes. chemokines such as mcp-1 induce their receptors to internalize in a β-arrestin-2-regulated and dynamin-dependent way. 23, 24 Because specific loss of ccr2-mediated β-arrestin recruitment to the plasma membrane, but not of ca 2+ mobilization, previously correlated with marked inhibition of ccr2-driven inflammation in a murine model of inflammatory arthritis, 18 we employed the internalization of alexa Fluor 647-labeled mcp-1 to visualize and to quantify the ccr2 antagonist-mediated effects. to this end, image analysis was performed based on the detection of internalized hmcp-1_aF647.
to enable confocal microscopic imaging of the monocytes, we exploited type i collagen-coated mtps as an adhesion substratum. During early steps of inflammation and wound healing, circulating human blood monocytes adhere to the blood vessel walls and migrate through the basement membrane to invade the affected areas of the surrounding tissues. in this process, the contact between monocytes and type i collagen of the extracellular matrix is critical for their adhesion and activation. 25 this interaction triggers various intracellular events, such as the enhancement of phagocytosis of opsonized bacteria, 26 the secretion of interleukin-1 (il-1), 27 and the increase in superoxide anion production. 25 notably, monocytes seeded on a tc-treated polystyrene surface showed a 2.4 times lower degree of internalization of the fluorescently labeled ligand in comparison to the cells applied to type i collagen ( fig. 3) . these results confirmed the importance of the interaction with an extracellular matrix protein for monocyte activation.
Quantitative representation and comparison of the functional properties of a range of ccr2 antagonists revealed that their apparent potencies are markedly influenced by the assay readout and format. although some of the compounds displayed similar potencies in the hca assay described herein and all four of the previously employed assay formats, other compounds revealed a more divergent pattern, with an up to more than 100-fold difference between the highest and the lowest potencies. hierarchical clustering of the compounds according to their response profiles in the five assay formats revealed some "assay/signal-biased" structure-activity relationships (i.e., certain chemotypes could be associated with particularly high or low potencies in one specific assay format compared to the other four readouts). expanding the matrix of ccr2 antagonists versus biological profiles will further elucidate the effects of specific compound substructures on the modulation of particular ccr2-dependent signaling pathways/assay readouts.
Because the signaling mechanisms mediating the cellular responses to chemokine receptor activation are likely to fall into at least two categories, one regulated by heterotrimeric g-proteins and the other controlled by β-arrestins, 17 it appears possible that the 24 ccr2 antagonists described here differentially affect these two coupling mechanisms. in fact, mathiesen et al. 28 have previously introduced the term biased antagonism to describe the complexities of the interaction of chemically distinct antagonists with various possible conformations of a single g-protein-coupled receptor resulting in different antagonist potencies with respect to different functional readouts. subsequently, other instances of biased antagonism and of potential therapeutic advantages of this mechanism have been noted.
For example, masri et al. 29 have shown that different classes of clinically effective antipsychotics share a common molecular mechanism involving inhibition of D2 l r/β-arrestin-2-mediated signaling while having various effects on D2 l rmediated g i/o protein activation, ranging from inverse to partial agonists and antagonists with highly variable efficacies and potencies. however, the latter study is not easily consistent with a report by klewe et al., 30 suggesting that β-arrestin and g-protein-coupling at the D2 receptor are tightly associated and orchestrated events.
alternative explanations for differences in relative potencies between different assays may have to be considered. examples are off-target effects, different readout kinetics, the use of equilibrium versus nonequilibrium assays, or distinct receptor reserves. although we cannot formally exclude off-target effects for the 24 ccr2 antagonists tested here, these compounds are ineffective at the two closest phylogenetic neighbors of ccr2, ccr1, and ccr3 (data not shown). With respect to the selectivity of the reference agonist mcp-1 for ccr2 employed here, it should be noted that ccr4 has previously been suggested to be activated by mcp-1 in Xenopus laevis oocytes. 31 subsequent experimentation, however, did not confirm these findings in mammalian cells. 32 at this point, we cannot ultimately decide whether the observed "assay/signal-biased" structure-activity relationships of the test compounds are due to (1) different antagonist-stabilized receptor conformations (i.e., bona fide functional selectivity), (2) different kinetics of assay readouts, or (3) distinct receptor reserves between the cellular assay systems. irrespective of its mechanistic basis, however, the information with respect to the "assay/ signal-biased" selectivity of test compounds is of high value in the drug discovery process because it allows the identification of the best match(es) between the structure-activity relationships of cellular in vitro assays and well-approved disease-modeling in vivo assays.
in the case of ccr2 antagonists, it is currently unknown whether the functional selectivity observed in vitro will translate into particular in vivo functions. however, the pleiotropic effects of ccr2 in both health and disease, ranging from monocyte chemotaxis to many specialized responses in hematopoietic and nonhematopoietic cells, 33, 34 suggest that this possibility may exist. For example, ccr2 is also necessary for organ-specific homing of bone marrow-derived multipotent mesenchymal stem cells to the heart in a transgenic mouse model and into hearts damaged by ischemia/reperfusion. 35, 36 therefore, the selective antagonization of a particular signaling pathway relevant in vivo may turn out to be superior. Furthermore, millennium's humanized anti-ccr2 monoclonal antibody ml-1202 appears to be most promising in multiple sclerosis treatment but apparently failed to show improvement in a rheumatoid arthritis trial, 22 consistent with the view that this ccr2 inhibitor may lack some of the qualities intrinsic to other ccr2 antagonists. 18 the jury is still out on the medical need for signaling-biased ccr2 antagonists. Whatever the final verdict on this issue will be, the broader in vitro profiling of candidate compounds in various assay formats as described in this work may allow us in the future to better match in vivo findings with particular pathway efficacies of test compounds. on this basis, the most disease-relevant in vitro parameter can be picked for further rounds of early drug candidate selection.
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